Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.77 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.77 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.77 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.77 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301171 | 0.91 | PIK3CD (0.75) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL27796474 | 0.91 | PIK3CD (0.70) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL300847 | 0.88 | PIK3CD (0.71) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL300955 | 0.86 | PIK3CD (0.72) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL301188 | 0.86 | PIK3CD (0.78) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL300865 | 0.86 | PIK3CD (0.84) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL300834 | 0.85 | PIK3CD (0.69) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL300915 | 0.84 | PIK3CD (0.72) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL11939631 | 0.83 | PIK3CD (0.82) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL300830 | 0.82 | PIK3CD (0.66) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679432-B | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2015-04-22 | — | — | CN | claimed |
| US-8383634-B2 | Methods of treatment using heteroaryl compounds and compositions thereof | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | claimed |
| EP-2078018-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2012-03-14 | — | — | EP | claimed |
| CN-109846884-A | With TOR kinase inhibitor for treating cancer | 西格诺药品有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-105039520-A | Identification of gene expression profile as a predictive biomarker for lkb1 status | SIGNAL PHARM LLC | 2015-11-11 | — | — | CN | disclosed |
| CN-101679432-B | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2015-04-22 | — | — | CN | disclosed |
| CN-104271139-A | Treatment of cancer with tor kinase inhibitors | SIGNAL PHARM LLC | 2015-01-07 | — | — | CN | disclosed |
| CN-104271138-A | Treatment of cancer with tor kinase inhibitors | SIGNAL PHARM LLC | 2015-01-07 | — | — | CN | disclosed |
| CN-103857804-A | Identification of gene expression profiles as predictive biomarkers for LKB1 status | SIGNAL PHARM LLC | 2014-06-11 | — | — | CN | disclosed |
| EP-2078018-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008051494-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |